Metabolic syndrome in patients with prostate cancer
Keywords:
Prostate cancer, Prostate-specifi c antigen, Metabolic syndrome X, Obesity, HyperglycemiaAbstract
CONTEXT AND OBJECTIVE: Prostate cancer (PCa) is the second most common cancer among men in Brazil. Recently, several studies have hypothesized a relationship between PCa and metabolic syndrome (MS). The aim here was to identify an association between MS and PCa. DESIGN AND SETTING: Cross-sectional study, Fundação de Benefi cência Hospital de Cirurgia (FBHC) and Universidade Federal de Sergipe. METHODS: Laboratory and anthropometric parameters were compared between PCa patients (n = 16) and controls (n = 16). RESULTS: The PCa patients showed signifi cantly greater frequency of MS than did the controls (p = 0.034). Serum glucose was higher and high-density lipoprotein-cholesterol was lower than in the controls, although without signifi cant differences. There were signifi cant differences in blood pressure (p = 0.029) and waist-to-hip ratio (p = 0.004). Pearson linear correlation showed a positive association between waist-to-hip ratio and prostate specifi c antigen (r = 0.584 and p = 0.028). Comparing subgroups with and without MS among the PCa patients, signifi cant differences (p < 0.05) in weight, height, body mass index, hip circumference and lean body mass were observed, thus showing higher central obesity in those with MS. The serum glucose values were also higher in MS patients (p = 0.006), thus demonstrating that insulin resistance has a role in MS physiopathology. CONCLUSIONS: Our study suggests that MS may exert an infl uence on the development of PCa. However, it would be necessary to expand the investigation fi eld with larger sample sizes and cohorts studied, to test the hypothesis generated in this study.
Downloads
References
Brasil. Ministério da Saúde. Secretaria Nacional de Assistência à Saúde. Instituto Nacional de Câncer. Coordenação de Preven- ção e Vigilância — Conprev. Câncer da Próstata: consenso. Rio de Janeiro: INCA; 2002. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/inca/manual_prostata.pdf. Accessed in 2008 (Jul 16).
Fowke JH, Signorello LB, Chang SS, et al. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer. 2006;107(10):2361-7.
Sociedade Brasileira de Hipertensão. Conceituação, epidemiolo- gia e diagnóstico. Revista da Sociedade Brasileira de Hipertensão.
;7(4):130-1. Available from: http://www.sbh.org.br/novo/arquivos/documentos/22.pdf. Accessed in 2008 (Aug 12).
Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85(1):60-7.
Oliveira EP, Souza MLA, Lima MDA. Prevalência de síndrome metabólica em uma área rural do semi-árido baiano. [Prevalence of metabolic syndrome in a semi-arid rural area in Bahia]. Arq Bras Endocrinol Metab. 2006;50(3):456-65.
Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28(11):2745-9.
Hammarsten J, Högstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005;41(18):2887-95.
Gomella LG, Labrie F, Gamito EJ, Brawer MK. Prostate cancer: risk assessment and diagnostic approaches. Rev Urol. 2001;3(Suppl 2):S31-8.
Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115(4):959-68.
Mydlo JH, Tieng NL, Volpe MA, Chaiken R, Kral JG. A pilot study analyzing PSA, serum testosterone, lipid profile, body mass index and race in a small sample of patients with and without carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2001;4(2):101-5.
Thompson MM, Garland C, Barrett-Connor E, Khaw KT, Friedlander NJ, Wingard DL. Heart disease risk factors, diabetes, and prostatic cancer in an adult community. Am J Epidemiol. 1989;129(3):511-7.
Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1997;6(8):557-63.
Sox HC. Current controversies in screening: cholesterol, breast cancer, and prostate cancer. Mt Sinai J Med. 1999;66(2):91-101.
Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA. Anthropometry in relation to prostate cancer risk in the Neth- erlands Cohort Study. Am J Epidemiol. 2000;151(6):541-9.
MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control. 2006;17(8):989-1003.
Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187-93.
International Diabetes Federation. The IDF consensus world- wide definition of the metabolic syndrome, 2005. Available from: http://www.idf.org/webdata/docs/Metac_syndrome_def.pdf. Accessed in 2008 (Jul 17).
Sociedade Brasileira de Hipertensão. V Diretrizes Brasileiras de Hipertensão Arterial. Hipertensão. 2006. Available from: http://www.sbn.org.br/Diretrizes/V_Diretrizes_Brasileiras_de_Hipertensao_Arterial.pdf. Accessed in 2008 (Jul 17).
Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966;50(3):125-8.
Sociedade Brasileira de Análises Clínicas. Secretarias Técnicas. Comitê Brasileiro de Análises Clínicas e Diagnóstico in vitro, 1998. Normas desenvolvidas pelo CB-36. Available from: http://www.sbac.org.br/pt/conteudos/secretarias_tecnicas/abnt_cb_36.htm#2. Accessed in 2008 (Aug 13).
Tulinius H, Sigfússon N, Sigvaldason H, Bjarnadóttir K, Tryggvadóttir L. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomarkers Prev. 1997;6(11):863-73.
World Health Organization. Definition, diagnosis and classifica- tion of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mel- litus. World Health Organization, 1999. Available from: http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf. Accessed in 2008 (Jul 17).
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a pro- spectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-38.
Veierod MB, Laake P, Thelle DS. Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men. Int J Cancer. 1997;73(5):634-8.
Irani J, Lefebvre O, Murat F, Dahmani L, Doré B. Obesity in re- lation to prostate cancer risk: comparison with a population hav- ing benign prostatic hyperplasia. BJU Int. 2003;91(6):482-4.
Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol. 2001;11(8):534-42.
Engeland A, Tretli S, Bjorge T. Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br J Cancer. 2003;89(7):1237-42.
Severson RK, Grove JS, Nomura AM, Stemmermann GN. Body mass and prostatic cancer: a prospective study. BMJ. 1988;297(6650):713-5.
MacInnis RJ, English DR, Gertig DM, Hopper JL, Giles GG. Body size and composition and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12(12):1417-21.
Maturo G, Vespasiani G, Mohamed EI, et al. Evaluating body composition of Italian prostate cancer patients without metastases. Acta Diabetol. 2003;40(Suppl 1):S168-70.
Alexopoulos CG, Blatsios B, Avgerinos A. Serum lipids and lipoprotein disorders in cancer patients. Cancer. 1987;60(12):3065-70.
Fiorenza AM, Branchi A, Sommariva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res. 2000;30(3):141-5.
Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 1989;49(7):1857-60.
Fournier DB, Erdman JW Jr, Gordon GB. Soy, its com- ponents, and cancer prevention: a review of the in vitro, animal, and human data. Cancer Epidemiol Biomarkers Prev. 1998;7(11):1055-65.
Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, Hsing AW. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev. 2003;12(7):665-8.
Lee IM, Sesso HD, Chen JJ, Paffenbarger RS Jr. Does physical activity play a role in the prevention of prostate cancer? Epide- miol Rev. 2001;23(1):132-7.
Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr. 2002;132(11 Suppl):3456S-64S.
Friedenreich CM, McGregor SE, Courneya KS, Angyalfi SJ, El- liott FG. Case-control study of lifetime total physical activity and prostate cancer risk. Am J Epidemiol. 2004;159(8):740-9.
